199807-35-7 Usage
General Description
Cilengitide trifluoroacetate is a powerful synthetic chemical compound notable for its capability to inhibit angiogenesis, the process through which new blood vessels form from pre-existing ones. Cilengitide trifluoroacetate is recognized as a specific integrin antagonist that primarily targets integrins αvβ3 and αvβ5, both of which are important players in angiogenesis. By specifically blocking these integrins, Cilengitide can hinder the growth of new blood vessels. This functionality has led it to be studied as a potential treatment for conditions that involve excessive angiogenesis, such as cancer. However, although shown promise in preclinical and early clinical testing, Cilengitide did not meet the expectancies in phase III clinical trials for glioblastoma.
Check Digit Verification of cas no
The CAS Registry Mumber 199807-35-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,9,8,0 and 7 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 199807-35:
(8*1)+(7*9)+(6*9)+(5*8)+(4*0)+(3*7)+(2*3)+(1*5)=197
197 % 10 = 7
So 199807-35-7 is a valid CAS Registry Number.
199807-35-7Relevant articles and documents
Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
-
Page/Page column 19-20, (2008/06/13)
The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amoun
